Douglas J. Swirsky
Douglas J. Swirsky's purchase track record
Douglas J. Swirsky has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2025 | MXCT | $65K | +14.5% | -47.1% | +7.3% |
| 9/14/2021 | CLRB | $26K | -33.7% | -54.8% | -4.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cellectar to Present Iopofosine Data at Waldenström Workshop. Cellectar Biosciences plans to share efficacy data from the Phase 2 CLOVER trial at an upcoming international workshop. The presentation will focus on patients with Waldenström Macroglobulinemia who did not respond to BTK inhibitor therapy. This data point is relevant for observers tracking the progress of the company's lead candidate, iopofosine I 131.
Transaction History
| MXCT | ▼ Sell | Open Market | 10,142 | $8K | 3/17/2026 | View on chart |
| MXCT | ▲ Buy | Open Market | 50,000 | $65K | 8/13/2025 | View on chart |
| MXCT | ▼ Sell | Open Market | 6,939 | $22K | 3/18/2025 | View on chart |
| MXCT | ▲ Buy | Grant | 37,500 | $0 | 3/14/2025 | View on chart |
| MXCT | ▲ Buy | Grant | 81,250 | $0 | 3/15/2024 | View on chart |
| CLRB | ▲ Buy | Open Market | 25,000 | $26K | 9/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
MaxCyte Appoints New Chief Corporate Development Officer
MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.
MaxCyte Appoints New Chief Corporate Development Officer. MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.